<DOC>
	<DOCNO>NCT01163799</DOCNO>
	<brief_summary>The purpose study ass Alefacept combination alemtuzumab induction calcineurin inhibitor corticosteroid withdrawal .</brief_summary>
	<brief_title>A Pilot Study Assess Safety Efficacy Alefacept de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description>This single center , investigator initiate , pilot study assess safety efficacy Alefacept combination Alemtuzumab induction Myfortic rapid steroid calcineurin inhibitor withdrawal de novo Kidney transplant recipient . Induction therapy involve single dose Alemtuzumab steroids peri-operatively . Tacrolimus administer first 30 day post-transplantation . Alefacept administer IV first two dos follow subcutaneous injection weekly 12 week post-transplant follow monthly injection rest duration study . The primary outcome safety efficacy outcome , include biopsy proven acute rejection episode , infectious complication serious adverse event . Secondary outcome include T-helper differentiation , cytokine production T regulatory cell generation assess immune monitoring assay .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Institutional Review Board ( IRB ) approve write Informed Consent Health Insurance Portability Accountability Act ( HIPAA ) Authorization U.S. site , equivalent privacy language per national regulation , obtain subject legally authorize representative prior studyrelated procedure ( include withdrawal prohibit medication , applicable ) Recipient kidney nonHLA identical related living donor , non related living donor , decease donor Recipient de novo kidney transplant ≥ 18 year age Anticipated receive first oral dose tacrolimus within 48 hour transplant procedure Female subject child bear potential must negative urine serum pregnancy test , must agree maintain effective birth control study Healthy donor eligible blood draw : Institutional Review Board ( IRB ) approve write Informed Consent Health Insurance Portability Accountability Act ( HIPAA ) Authorization U.S. site , equivalent privacy language per national regulation , obtain subject prior studyrelated procedure Subject donor de novo kidney transplant subject enrol study self declare healthy volunteer kidney donor subject enrol study ≥ 18 year age Previously receive receive organ transplant kidney Sensitivity iodine Will receive transplant nonheart beat donor ( donation cardiac death DCD ) Receives transplant HLA identical relate live donor Will receive solitary kidney decease donor &lt; 5 year age Will receive kidney anticipate cold ischemia time ( CIT ) &gt; 30 hour Will receive ABO incompatible donor kidney Recipient donor know seropositive human immunodeficiency virus ( HIV ) Recipient positive T B cell crossmatch investigational site 's standard method determination . For recipient flow cytometry crossmatch perform positive either T B cell testing , recipient exclude donor specific , antiHLA antibody detect flow cytometry base , specific antiHLA antibody test . Current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully Significant liver disease Serologically negative cytomegalovirus ( CMV ) serologically positive CMV donor Serologically negative Epstein Barr virus Has receive intravenous immunoglobulin ( IVIG ) therapy three month prior first dose study drug Uncontrolled concomitant infection unstable medical condition could interfere study objective Concurrently participate another drug study receive investigational drug within 28 day prior transplant Known hypersensitivity alefacept , alemtuzumab , tacrolimus , mycophenolic acid , corticosteroid , component Any form substance abuse , psychiatric disorder , condition opinion Investigator could invalidate communication Investigator Subject pregnant lactating Subject unlikely comply visit schedule protocol Subject receive kidney transplant expand criterion donor ( ECD ) Will receive kidney transplant CDC high risk donor Healthy donor subject exclude participation follow apply : Unable comprehend investigational nature protocol participation Complete blood count result determine outside normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
	<keyword>Northwestern</keyword>
	<keyword>Calcineurin Inhibitor</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Steroid avoidance</keyword>
</DOC>